These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29489886)

  • 1. Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
    de Jong MRW; Visser L; Huls G; Diepstra A; van Vugt M; Ammatuna E; van Rijn RS; Vellenga E; van den Berg A; Fehrmann RSN; van Meerten T
    PLoS One; 2018; 13(2):e0193098. PubMed ID: 29489886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
    Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
    Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
    Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
    Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.
    Qiu H; Li J; Feng Z; Yuan J; Lu J; Hu X; Gao L; Lv S; Yang J; Chen L
    Clin Exp Pharmacol Physiol; 2016 Sep; 43(9):795-801. PubMed ID: 27247195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma.
    Zhang JY; Zhang PP; Zhou WP; Yu JY; Yao ZH; Chu JF; Yao SN; Wang C; Lone W; Xia QX; Ma J; Yang SJ; Liu KD; Dong ZG; Guo YJ; Smith LM; McKeithan TW; Chan WC; Iqbal J; Liu YY
    Clin Cancer Res; 2019 Jul; 25(13):4168-4178. PubMed ID: 30824586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
    Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K
    Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.
    Johnson NA; Leach S; Woolcock B; deLeeuw RJ; Bashashati A; Sehn LH; Connors JM; Chhanabhai M; Brooks-Wilson A; Gascoyne RD
    Haematologica; 2009 Mar; 94(3):423-7. PubMed ID: 19211644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
    Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
    Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
    Wang L; Wang W; Li X; Guo Y; Zhu X
    Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
    Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
    Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.
    Johnson NA; Boyle M; Bashashati A; Leach S; Brooks-Wilson A; Sehn LH; Chhanabhai M; Brinkman RR; Connors JM; Weng AP; Gascoyne RD
    Blood; 2009 Apr; 113(16):3773-80. PubMed ID: 19029441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent administration of rituximab and CHOP chemotherapeutic agents for outpatients with CD20-positive lymphoma.
    Yakushijin Y; Tatsukawa T; Yamaguchi T; Egawa T; Hidaka N; Ido K; Suemaru K; Yasukawa M; Araki H
    Anticancer Agents Med Chem; 2012 Sep; 12(7):829-34. PubMed ID: 22721383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
    [No Abstract]   [Full Text] [Related]  

  • 18. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
    Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.
    Thomsen EA; Rovsing AB; Anderson MV; Due H; Huang J; Luo Y; Dybkaer K; Mikkelsen JG
    Mol Oncol; 2020 Sep; 14(9):1978-1997. PubMed ID: 32585766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
    Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
    Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.